Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Trial Landscape in NASH.
Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M. Harrison SA, et al. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2001-2014. doi: 10.1016/j.cgh.2023.03.041. Epub 2023 Apr 12. Clin Gastroenterol Hepatol. 2023. PMID: 37059159 Free article. Review.
Controversies in the Diagnosis and Management of NAFLD and NASH.
Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Rinella ME, et al. Among authors: harrison sa. Gastroenterol Hepatol (N Y). 2014 Apr;10(4):219-27. Gastroenterol Hepatol (N Y). 2014. PMID: 24976805 Free PMC article.
Practice patterns in NAFLD and NASH: real life differs from published guidelines.
Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Rinella ME, et al. Among authors: harrison sa. Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581. Therap Adv Gastroenterol. 2016. PMID: 26770262 Free PMC article.
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Among authors: harrison sa. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E. Friedman SL, et al. Among authors: harrison sa. Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29. Hepatology. 2018. PMID: 28833331 Free PMC article. Clinical Trial.
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Siddiqui MS, et al. Among authors: harrison sa. Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22. Hepatology. 2018. PMID: 29059456 Free PMC article.
Pharmacotherapy for NASH: Current and emerging.
Konerman MA, Jones JC, Harrison SA. Konerman MA, et al. Among authors: harrison sa. J Hepatol. 2018 Feb;68(2):362-375. doi: 10.1016/j.jhep.2017.10.015. Epub 2017 Nov 6. J Hepatol. 2018. PMID: 29122694 Review.
372 results